Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Hostname: page-component-559fc8cf4f-rz424 Total loading time: 0.583 Render date: 2021-03-04T16:44:24.890Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }
EnglishFrançais
British Journal of Nutrition British Journal of Nutrition

Article contents

FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease

Published online by Cambridge University Press:  17 November 2020

Feng Gao ,
Kenneth I. Zheng ,
Pei-Wu Zhu ,
Yang-Yang Li ,
Hong-Lei Ma ,
Gang Li ,
Liang-Jie Tang ,
Rafael S. Rios ,
Wen-Yue Liu ,
Xiao-Yan Pan ,
Giovanni Targher ,
Christopher D. Byrne ,
Yong-Ping Chen  and
Ming-Hua Zheng [Opens in a new window]
Feng Gao
Affiliation:
Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Kenneth I. Zheng
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Pei-Wu Zhu
Affiliation:
Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Yang-Yang Li
Affiliation:
Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Hong-Lei Ma
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Gang Li
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Liang-Jie Tang
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Rafael S. Rios
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Wen-Yue Liu
Affiliation:
Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Xiao-Yan Pan
Affiliation:
Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
Giovanni Targher
Affiliation:
Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37100 Verona, Italy
Christopher D. Byrne
Affiliation:
Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
Yong-Ping Chen
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China Institute of Hepatology, Wenzhou Medical University, Wenzhou 325000, People’s Republic of China Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou 325000, People’s Republic of China
Ming-Hua Zheng
Affiliation:
Department of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China Institute of Hepatology, Wenzhou Medical University, Wenzhou 325000, People’s Republic of China Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou 325000, People’s Republic of China
Corresponding
E-mail address:
zhengmh@wmu.edu.cn
Get access
Rights & Permissions[Opens in a new window]

Abstract

The FNDC5 gene encodes the fibronectin type III domain-containing protein 5 that is a membrane protein mainly expressed in skeletal muscle, and the FNDC5 rs3480 polymorphism may be associated with liver disease severity in non-alcoholic fatty liver disease (NAFLD). We investigated the influence of the FNDC5 rs3480 polymorphism on the relationship between sarcopenia and the histological severity of NAFLD. A total of 370 adult individuals with biopsy-proven NAFLD were studied. The association between the key exposure sarcopenia and the outcome liver histological severity was investigated by binary logistic regression. Stratified analyses were undertaken to examine the impact of FNDC5 rs3480 polymorphism on the association between sarcopenia and the severity of NAFLD histology. Patients with sarcopenia had more severe histological grades of steatosis and a higher prevalence of significant fibrosis and definite non-alcoholic steatohepatitis than those without sarcopenia. There was a significant association between sarcopenia and significant fibrosis (adjusted OR 2·79, 95 % CI 1·31, 5·95, P = 0·008), independent of established risk factors and potential confounders. Among patients with sarcopenia, significant fibrosis occurred more frequently in the rs3480 AA genotype carriers than in those carrying the FNDC5 rs3480 G genotype (43·8 v. 17·2 %, P = 0·031). In the association between sarcopenia and liver fibrosis, there was a significant interaction between the FNDC5 genotype and sarcopenia status (P value for interaction = 0·006). Sarcopenia is independently associated with significant liver fibrosis, and the FNDC5 rs3480 G variant influences the association between sarcopenia and liver fibrosis in patients with biopsy-proven NAFLD.

Keywords

Sarcopenia Non-alcoholic fatty liver disease Skeletal muscle SNP appendicular skeletal muscle mass bioelectrical impedance analyser fibronectin type III domain-containing protein 5 non-alcoholic fatty liver disease non-alcoholic steatohepatitis
Type
Full Papers
Information
British Journal of Nutrition , First View , pp. 1 - 12
Check for updates
Copyright
© The Author(s), 2020. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below.
If you should have access and can't see this content please contact technical support.

References

Marty, E, Liu, Y, Samuel, A, et al. (2017) A review of sarcopenia: enhancing awareness of an increasingly prevalent disease. Bone 105, 276–286.CrossRefGoogle ScholarPubMed
Lee, Y-h, Kim, SU, Song, K, et al. (2016) Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008–2011). Hepatology 63, 776–786.CrossRefGoogle Scholar
Hong, HC, Hwang, SY, Choi, HY, et al. (2014) Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 59, 1772–1778.CrossRefGoogle ScholarPubMed
Peng, T-C, Wu, L-W, Chen, W-L, et al. (2019) Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): the importance of sarcopenia definition. Clin Nutr 38, 422–428.CrossRefGoogle Scholar
Xia, M-F, Chen, L-Y, Wu, L, et al. (2019) The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. Aliment Pharmacol Ther 50, 684–695.CrossRefGoogle ScholarPubMed
Mesinovic, J, Zengin, A, De Courten, B, et al. (2019) Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes 12, 1057–1072.CrossRefGoogle ScholarPubMed
Karstoft, K & Pedersen, BK (2016) Skeletal muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr Metab Care 19, 270–275.CrossRefGoogle ScholarPubMed
Gomarasca, M, Banfi, G & Lombardi, G (2020) Myokines: the endocrine coupling of skeletal muscle and bone. Adv Clin Chem 94, 155–218.CrossRefGoogle ScholarPubMed
Perakakis, N, Triantafyllou, GA, Fernández-Real, JM, et al. (2017) Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 13, 324–337.CrossRefGoogle ScholarPubMed
Petta, S, Valenti, L, Svegliati-Baroni, G, et al. (2017) Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 102, 2660–2669.CrossRefGoogle ScholarPubMed
Metwally, M, Bayoumi, A, Romero-Gomez, M, et al. (2019) A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3’UTR. J Hepatol 70, 494–500.CrossRefGoogle ScholarPubMed
Hu, DS, Zhu, SH, Liu, WY, et al. (2020) PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab 46, 496–503.CrossRefGoogle ScholarPubMed
Zheng, KI, Fan, JG, Shi, JP, et al. (2020) From NAFLD to MAFLD: a “redefining” moment for fatty liver disease. Chin Med J 133, 2271–2273.CrossRefGoogle ScholarPubMed
Lonardo, A & Suzuki, A (2020) Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med 9, 1278.CrossRefGoogle ScholarPubMed
Capozza, RF, Cointry, GR, Cure-Ramírez, P, et al. (2004) A DXA study of muscle–bone relationships in the whole body and limbs of 2512 normal men and pre- and post-menopausal women. Bone 35, 283–295.CrossRefGoogle ScholarPubMed
Goda, A & Masuyama, T (2016) Obesity and overweight in Asian people. Circ J 80, 2425–2426.CrossRefGoogle ScholarPubMed
Alberti, KGMM, Eckel, RH, Grundy, SM, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645.CrossRefGoogle Scholar
Koo, BK, Kim, D, Joo, SK, et al. (2017) Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 66, 123–131.CrossRefGoogle ScholarPubMed
Kim, Y-S, Lee, Y, Chung, Y-S, et al. (2012) Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci 67, 1107–1113.CrossRefGoogle ScholarPubMed
Kleiner, DE, Brunt, EM, Van Natta, M, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321.CrossRefGoogle ScholarPubMed
Brunt, EM, Janney, CG, Di Bisceglie, AM, et al. (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467–2474.CrossRefGoogle ScholarPubMed
Canivet, CM, Bonnafous, S, Rousseau, D, et al. (2020) Hepatic FNDC5 is a potential local protective factor against non-alcoholic fatty liver. Biochim Biophys Acta, Mol Basis Dis 1866, 165705.CrossRefGoogle ScholarPubMed
Cai, C, Song, X, Chen, Y, et al. (2020) Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Int 14, 115–126.CrossRefGoogle ScholarPubMed
Castera, L, Friedrich-Rust, M & Loomba, R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264–1281.CrossRefGoogle ScholarPubMed
Petta, S, Ciminnisi, S, Di Marco, V, et al. (2017) Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45, 510–518.CrossRefGoogle ScholarPubMed
Doycheva, I, Watt, KD & Alkhouri, N (2017) Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 65, 2100–2109.CrossRefGoogle Scholar
Barazzoni, R, Bischoff, S, Boirie, Y, et al. (2018) Sarcopenic obesity: time to meet the challenge. Obesity Facts 11, 294–305.CrossRefGoogle ScholarPubMed
Polyzos, SA, Anastasilakis, AD, Efstathiadou, ZA, et al. (2018) Irisin in metabolic diseases. Endocrine 59, 260–274.CrossRefGoogle ScholarPubMed
Shanaki, M, Moradi, N, Emamgholipour, S, et al. (2017) Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr 11, Suppl. 1, S467–S472.CrossRefGoogle ScholarPubMed
Zhang, H-J, Zhang, X-F, Ma, Z-M, et al. (2013) Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 59, 557–562.CrossRefGoogle ScholarPubMed
Cleasby, ME, Jamieson, PM & Atherton, PJ (2016) Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol 229, R67–R81.CrossRefGoogle ScholarPubMed
Montalcini, T, Pujia, A, Donini, LM, et al. (2020) A call to action: now is the time to screen elderly and treat osteosarcopenia, a position paper of the Italian College of Academic Nutritionists MED/49 (ICAN-49). Nutrients 12, 2662.CrossRefGoogle Scholar
Kim, G, Lee, S-E, Lee, Y-B, et al. (2018) Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 68, 1755–1768.CrossRefGoogle ScholarPubMed
Bosy-Westphal, A, Jensen, B, Braun, W, et al. (2017) Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. Eur J Clin Nutr 71, 1061–1067.CrossRefGoogle ScholarPubMed

Gao et al. Supplementary Materials

Gao et al. Supplementary Materials

File 29 KB

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 30
Total number of PDF views: 107 *
View data table for this chart

* Views captured on Cambridge Core between 17th November 2020 - 4th March 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease
Available formats
×
×

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *